Get the Stockscreener App
58.08
0.03%
0.02
After Hours:
58.00
-0.08
-0.14%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $58.08, with a volume of 7.61M.
It is up +0.03% in the last 24 hours and down -1.69% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$58.06
Open:
$57.9
24h Volume:
7.61M
Relative Volume:
0.60
Market Cap:
$118.58B
Revenue:
$48.19B
Net Income/Loss:
$7.06B
P/E Ratio:
16.79
EPS:
3.4587
Net Cash Flow:
$12.85B
1W Performance:
+0.71%
1M Performance:
-1.69%
6M Performance:
+32.60%
1Y Performance:
+13.13%
1-Day Range:
$57.56
$58.62
1-Week Range:
$57.55
$59.80
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.08 | 119.69B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
922.50 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.10 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
210.26 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.38 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.96 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol-Myers Squibb Company stock (US0897961004): Why does its oncology dominance matter more now f - AD HOC NEWS
Bristol Myers Squibb: Value Stock Analysis for Dividend Investors in 2026News and Statistics - IndexBox
Is Bristol-Myers Squibb Company (BMY) Among the 15 Cash-Rich Dividend Stocks to Invest in Right Now - Insider Monkey
American Express Company (AXP) – One of the 15 Cash-Rich Dividend Stocks to Invest in Right Now - Insider Monkey
Chemotherapy Market Set to Witness Massive Growth Through 2033 - openPR.com
Bristol Myers Squibb's Stock Position Boosted by Burney Co. - National Today
Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036 - GlobeNewswire Inc.
Bristol Myers Squibb Company $BMY Stock Position Lifted by Burney Co. - MarketBeat
Ritholtz Wealth Management Boosts Stake in Bristol Myers Squibb - National Today
Bartlett & CO. Wealth Management LLC Has $7.26 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Assessing Bristol Myers Squibb (BMY) Valuation After Camzyos Data And T Cell Engager Collaboration News - Yahoo Finance
BMS and Oxford BioTherapeutics join forces in TCE discovery pact - Pharmaceutical Technology
Bristol Myers Squibb stock (US1101221083): Is its oncology pipeline strong enough to unlock new upsi - AD HOC NEWS
Bristol Myers Squibb Cancer Alliance Adds Weight To Valuation Debate - Yahoo Finance
F&V Capital Management, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Bristol-Myers Squibb Company (BMY) stock price, news, quote and history - Yahoo Finance Singapore
Bristol-Myers Likely to Get Desired Court in Paxton Plavix Suit - Bloomberg Law News
Oxford BioTherapeutics Partners with Bristol Myers Squibb for Next-Gen T-Cell Therapies - National Today
Bristol-Myers Squibb Earnings Preview: What to Expect - Yahoo Finance
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours - Yahoo Finance UK
Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst - Insider Monkey
MFS Blended Research Core Equity Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst - Benzinga
Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's
Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com
Guggenheim reiterates Bristol-Myers Squibb stock rating at Buy By Investing.com - Investing.com India
Guggenheim reiterates Bristol-Myers Squibb stock rating at Buy - Investing.com
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline - Reuters
Inlet Private Wealth Reduces Bristol Myers Squibb Stake - National Today
Bristol-Myers Squibb Company (BRM.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol-Myers Squibb Company (BMY) latest stock news and headlines - Yahoo Finance UK
Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scotiabank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc - openpr.com
Nathan Pennell: "Global and Local" Model Takes Focus During BMS Japan Visit - Oncodaily
Case-By-Case Guide As Justices Eye Landmark Pharma Law - Law360
Trust Co. of Toledo NA OH Sells 55,523 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Element Squared LLC Acquires Shares of 48,420 Bristol Myers Squibb Company $BMY - MarketBeat
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock - Investing.com Australia
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance UK
BRISTOL-MYERS SQUIBB CO (BMYS.VI) Q1 FY2025 earnings call transcript - Yahoo Finance
Growth and Income Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term - Yahoo Finance
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):